New and emerging drugs in type 2 diabetes / 대한내과학회지
Korean Journal of Medicine
;
: 446-450, 2007.
Artículo
en Coreano
| WPRIM
| ID: wpr-162636
ABSTRACT
Recent advances in understanding insulin secretion, action and signaling have led to the development of new pharmacological agents. Several new emerging drugs and drug classes for the management of diabetes are under development, including the incretin mimetic agents (exenatide, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide 1 analogues), the amylin analogue pramlintide, the cannabinoid-1 receptor antagonist rimonabant, the mixed peroxisome proliferator-activated receptor agonists muraglitazar and the inhaled insulin preparation Exubera. New drugs and technologic advances being made available will help achieve the goals of treating patients with diabetes to all the appropriate metabolic targets. Longer term studies will help providers weigh the benefits, adverse effects, cost, and unknown long-term risks of these medications.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Peroxisomas
/
Péptido 1 Similar al Glucagón
/
Inhibidores de la Dipeptidil-Peptidasa IV
/
Incretinas
/
Polipéptido Amiloide de los Islotes Pancreáticos
/
Insulina
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS